Trials / Not Yet Recruiting
Not Yet RecruitingNCT07478302
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2524 Injection | SHR-2524 injection. |
| DRUG | Bevacizumab Injection | Bevacizumab injection. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-10-01
- Completion
- 2027-12-01
- First posted
- 2026-03-17
- Last updated
- 2026-03-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07478302. Inclusion in this directory is not an endorsement.